How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,451 results for

Incremental Cost Effectiveness Ratio

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology Full Text available with Trip Pro

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology Incremental cost-effectiveness ratios (ICERs) are used to assess the value for money of new drugs. Many believe that ICERs for drugs that treat rare diseases are much higher than those of common drugs. Our objective was to compare the proportion of ICERs that are cost effective for rare and common cancers.We used the Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry (...) to identify cost-effectiveness studies of pharmaceutical interventions for cancers. Studies that assessed FDA-approved 'orphan drugs' were categorized as assessing rare cancers. The proportion of common and rare cancer drugs that were cost effective at various ICER thresholds were compared along with study characteristics. Logistic regressions were conducted to assess important predictors of cost effectiveness.We identified 303 studies that reported 701 ICERs. Seventy nine percent (n = 240) of studies

2017 PharmacoEconomics open

2. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY? Full Text available with Trip Pro

What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY? The National Institute for Health and Care Excellence has recently proposed that company submissions with a base-case incremental cost-effectiveness ratio (ICER) of less than £10,000/quality-adjusted life-year (QALY) might be eligible for a "fast-track" appraisal.To explore

2018 Value in Health

3. Incremental Cost Effectiveness Ratio

Incremental Cost Effectiveness Ratio Incremental Cost Effectiveness Ratio Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Incremental (...) Cost Effectiveness Ratio Incremental Cost Effectiveness Ratio Aka: Incremental Cost Effectiveness Ratio , ICER From Related Chapters II. Definition: Incremental Cost Effectiveness Ratio (ICER) Based on cost for an outcome utility or value (e.g. ) Cost effectiveness can be determined by comparing ICER to a willingness to pay III. Technique Given Two strategies: 1 and 2 (e.g. treatment and no treatment) Calculation Incremental Cost Effectiveness Ratio (ICER) = Incremental_Cost

2018 FP Notebook

4. Economic analysis of three interventions of different intensity in improving school implementation of a government healthy canteen policy in Australia: costs, incremental and relative cost effectiveness. Full Text available with Trip Pro

Economic analysis of three interventions of different intensity in improving school implementation of a government healthy canteen policy in Australia: costs, incremental and relative cost effectiveness. No evaluations of the cost or cost effectiveness of interventions to increase school implementation of food availability policies have been reported. Government and non-government agency decisions regarding the extent of investment required to enhance school implementation of such policies (...) was undertaken. Secondly, an indirect comparison of the trials was undertaken to determine the most cost-effective of the three strategies. The economic analysis was based on the cost of delivering the interventions by health service delivery staff to increase the proportion of schools 'adherent' with the policy.The total costs per school were $166,971, $70,926 and $75,682 for the high, medium and low intensity interventions respectively. Compared to usual support, the cost effectiveness ratios for each

2018 BMC Public Health Controlled trial quality: uncertain

5. Incremental Cost-Effectiveness of Aspiration Therapy vs Bariatric Surgery and No Treatment for Morbid Obesity. (Abstract)

Incremental Cost-Effectiveness of Aspiration Therapy vs Bariatric Surgery and No Treatment for Morbid Obesity. Despite its recent approval by the US Food and Drug Administration and Health Canada, aspiration therapy-one of the latest weight loss treatments-remains controversial. Critics have expressed concerns that the therapy could lead to bulimia and other binge eating disorders. Meanwhile, proponents argue that the therapy is less invasive, reversible, and cheaper than bariatric surgery (...) . Cost-effectiveness of this therapy, however, is not yet established.We developed a Markov model to estimate the incremental cost-effectiveness of aspiration therapy relative to 2 most common bariatric surgery procedures (gastric bypass and sleeve gastrectomy) and no treatment over a lifetime horizon. Costs were estimated from the health system's perspective using US data. Effectiveness was measured in terms of quality-adjusted life-years (QALYs).Despite being a cheaper procedure than bariatric

2019 American Journal of Gastroenterology

6. Incremental clinical effectiveness and cost effectiveness of providing supervised physiotherapy in addition to usual medical care in patients with osteoarthritis of the hip or knee: 2-year results of the MOA randomised controlled trial. Full Text available with Trip Pro

Incremental clinical effectiveness and cost effectiveness of providing supervised physiotherapy in addition to usual medical care in patients with osteoarthritis of the hip or knee: 2-year results of the MOA randomised controlled trial. To investigate the clinical- and cost-effectiveness at 2-year follow-up of providing individual, supervised exercise physiotherapy and/or manual physiotherapy in addition to usual medical care.People with hip or knee osteoarthritis meeting the American College (...) of Rheumatology clinical diagnostic criteria were randomised (1:1, concealed, assessor-blinded) to four groups: usual medical care; supervised exercise physiotherapy; manual physiotherapy; or combined exercise and manual physiotherapy. Physiotherapy group participants were provided 10 50-min treatment sessions including booster sessions at 4 and 13 months, in addition to usual care. The primary outcome at 2-year follow-up was incremental cost-utility ratio (ICUR) of each physiotherapy intervention in addition

2018 Osteoarthritis and Cartilage Controlled trial quality: predicted high

7. Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data. Full Text available with Trip Pro

(standard error = £28.50) for metabolic and cardioprotective medication. For ADDITION-UK, over the 10-, 20-, and 30-year time horizon, adjusted incremental quality-adjusted life-years (QALYs) were 0.014, 0.043, and 0.048, and adjusted incremental costs were £1,021, £1,217, and £1,311, resulting in incremental cost-effectiveness ratios of £71,232/QALY, £28,444/QALY, and £27,549/QALY, respectively. Respective incremental cost-effectiveness ratios for ADDITION-Cambridge were slightly higher.The incremental (...) Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data. There is uncertainty about the cost effectiveness of early intensive treatment versus routine care in individuals with type 2 diabetes detected by screening.To derive a trial-informed estimate of the incremental costs of intensive treatment as delivered in the Anglo-Danish-Dutch Study of Intensive

2017 Value in Health Controlled trial quality: uncertain

8. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Full Text available with Trip Pro

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of different treatments for patients with severe or very severe chronic obstructive pulmonary disease. The authors concluded that the UK clinical practice was cost-effective

2012 NHS Economic Evaluation Database.

9. Incremental cost and cost-effectiveness of low-dose, high-frequency training in basic emergency obstetric and newborn care as compared to status quo: part of a cluster-randomized training intervention evaluation in Ghana Full Text available with Trip Pro

key parameters.For the 40 health facilities included in the evaluation, the total LDHF training cost was $823,134. During the follow-up period after the first LDHF training-1 year at each participating facility-approximately 544 lives were saved. With deterministic calculation, these findings translate to $1497.77 per life saved or $53.07 per DALY averted. Probabilistic sensitivity analysis, with mean incremental cost-effectiveness ratio of $54.79 per DALY averted ($24.42-$107.01), suggests (...) Incremental cost and cost-effectiveness of low-dose, high-frequency training in basic emergency obstetric and newborn care as compared to status quo: part of a cluster-randomized training intervention evaluation in Ghana Low-dose, high-frequency (LDHF) training is a new approach best practices to improve clinical knowledge, build and retain competency, and transfer skills into practice after training. LDHF training in Ghana is an opportunity to build health workforce capacity in critical areas

2017 Globalization and health Controlled trial quality: uncertain

10. Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis Full Text available with Trip Pro

Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis This study responds to a request in the National Institute for Health and Care Excellence (NICE) guidance to assess the impact of using alternative sources of utility values, applied to multiple sclerosis (MS).Incremental cost-effectiveness ratios (ICERs) were calculated using utility values based on UK and Dutch values of EQ-5D, two UK mappings and one Dutch mapping of EQ (...) of the model than did EQ-5D. The ICER of glatiramer acetate with EQ-5D was US$182,291 for The Netherlands and US$153,476 for the UK. Ratios for mapped and condition-specific utilities were between 20 and 60 % higher.The overestimation of quality of life of patients with MS by mapped EQ-5D or condition-specific utility values, relative to observed EQ-5D, increases the ICER substantially in a lifetime Markov model.

2016 PharmacoEconomics

11. Disinfection of Multi-Use Ocular Equipment for Ophthalmological Procedures: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

bleach as a disinfection technique of tonometers. Using alcohol swabs as a base case, the cost-effective analysis demonstrated that the incremental cost-effectiveness ratio for peroxide bleach was $12,152 Canadian dollars per epidemic keratoconjunctivitis averted. The identified guideline recommends that ophthalmic equipment be cleaned immediately as per the manufacturer’s written instruction of use based on strong evidence. Additional recommendations were general and with respect to how the cleaning (...) Disinfection of Multi-Use Ocular Equipment for Ophthalmological Procedures: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Disinfection of Multi-Use Ocular Equipment for Ophthalmological Procedures: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Disinfection of Multi-Use Ocular Equipment for Ophthalmological Procedures: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Disinfection

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Multidisciplinary Treatment Programs for Patients with Chronic Non-Malignant Pain: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines – An Update

in an incremental cost-effectiveness ratio exceeding standard willingness-to-pay thresholds. Findings from the current report are consistent with those from the 2017 CADTH Rapid Response report.2 Evidence regarding optimal pain management services suggests that there is a benefit from moving beyond the only use of medication to more comprehensive programs. However, further research is needed to identify the type of components and combinations that would provide optimal benefits for patients with chronic pain (...) Multidisciplinary Treatment Programs for Patients with Chronic Non-Malignant Pain: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines – An Update Multidisciplinary Treatment Programs for Patients with Chronic Non-Malignant Pain: A Review of Clinical Effectiveness, Cost-effectiveness, and Guidelines – An Update | CADTH.ca Find the information you need Multidisciplinary Treatment Programs for Patients with Chronic Non-Malignant Pain: A Review of Clinical Effectiveness, Cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

13. Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. (Abstract)

the mutation. Singapore-specific costs and prevalence of MODY obtained from local studies and utility values sourced from the literature are used to populate the model.The algorithm-driven MODY testing strategy has an incremental cost-effectiveness ratio of US$93 663 per quality-adjusted life year relative to the no testing strategy. If the price of genetic testing falls from US$1050 to US$530 (a 50% decrease), it will become cost-effective.Our proposed algorithm-driven testing strategy for MODY is not yet (...) Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore. Offering genetic testing for Maturity Onset Diabetes of the Young (MODY) to all young patients with type 2 diabetes has been shown to be not cost-effective. This study tests whether a novel algorithm-driven genetic testing strategy for MODY is incrementally cost-effective relative to the setting of no testing.A decision tree was constructed

2017 Journal of Medical Genetics

14. Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting. Full Text available with Trip Pro

was associated with an improvement of 0.05 quality-adjusted life years (QALYs) versus BBT, due to reductions in non-severe hypoglycaemic episodes and BMI with IDegLira. Costs were higher with IDegLira by GBP 303 per patient, leading to an incremental cost-effectiveness ratio (ICER) of GBP 5924 per QALY gained for IDegLira versus BBT. ICERs remained below GBP 20 000 per QALY gained across a range of sensitivity analyses.IDegLira is a cost-effective alternative to BBT with insulin glargine U100 plus insulin (...) Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting. To evaluate the cost-effectiveness of IDegLira versus basal-bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.A Microsoft Excel model was used to evaluate the cost-utility of IDegLira

2018 obesity & metabolism

15. Cost-effectiveness of rapid point-of-care testing (POCT) programs for HIV

is the cost-effectiveness of these programs determined? Key take-home messages Studies suggest that rapid HIV tests can be cost-effective in high-income settings under various scenarios (1–5). Criteria to examine the cost-effectiveness of rapid tests for HIV include cost per test conducted and cost per reactive test (4, 6), cost per quality adjusted life year (QALY) 1 gained (5, 7-11), and an incremental cost-effectiveness ratio (ICER or $/QALY) 2 (1, 12–14) which compares cost and outcomes of an HIV (...) : sexually transmitted infection clinics, routine screening in hospital emergency departments, and diagnoses made in inpatient settings (14). The study ran a model for 10,000 index patients for each setting in order to examine alternative scenarios (14). To measure cost-effectiveness, the study calculated the incremental cost-effectiveness ratio for each scenario. The study found that diagnosing persons in emergency department settings was cost-saving compared with diagnosing persons in inpatient

2020 Ontario HIV Treatment Network

16. Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA

Cost-effectiveness analysis: Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA | BMJ Evidence-Based Medicine We use cookies to improve our (...) * Password * your user name or password? You are here Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA Article Text Therapeutics Cost-effectiveness analysis Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics

2010 Evidence-Based Medicine

17. A review of the evidence base for modelling the costs of overweight, obesity and diet-related illness for Scotland, and critical appraisal of the cost-effectiveness evidence base for population wide interventions to reduce overweight, obesity and diet-rel

A review of the evidence base for modelling the costs of overweight, obesity and diet-related illness for Scotland, and critical appraisal of the cost-effectiveness evidence base for population wide interventions to reduce overweight, obesity and diet-rel 1 A review of the evidence base for modelling the costs of overweight, obesity and diet-related illness for Scotland, and critical appraisal of the cost-effectiveness evidence base for population wide interventions to reduce overweight (...) of methods 10 1.4 Structure of the report 10 2 Evidence base relating to the costs of overweight, obesity and diet-related illness 11 2.1 Overview of cost of illness methods 11 Figure 1 Overview of costs 12 2.2 Literature search 14 Figure 2 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analyses) flow chart of cost of illness studies 16 Included 16 Eligibility 16 Screening 16 Identification 16 2.3 Results and critical appraisal 17 2.4 Summary and conclusions 22 3 Cost-effectiveness

2017 Health Economics Research Unit

18. Incremental cost-effectiveness of various monthly doses of vardenafil Full Text available with Trip Pro

presented in line graphs. Results The QALYs gained were 10.13 for no vardenafil; 11.36 for four doses a month; 11.50 for six doses a month; and 11.57 for eight doses a month. The monthly costs were zero for no vardenafil; $707.70 for four doses; $1,061.60 for six doses; and $1,415.50 for eight doses. The incremental cost per QALY gained for four doses, compared with none, was $576. The incremental cost-effectiveness ratio (ICER) for six doses, compared with four, was $2,585. The ICER for eight doses (...) Incremental cost-effectiveness of various monthly doses of vardenafil Incremental cost-effectiveness of various monthly doses of vardenafil Incremental cost-effectiveness of various monthly doses of vardenafil Aspinall SL, Smith KJ, Cunningham FE, Good CB Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment

2011 NHS Economic Evaluation Database.

19. Cost-effectiveness, cost-utility and the budget impact of antidepressants versus preventive cognitive therapy with or without tapering of antidepressants. Full Text available with Trip Pro

antidepressants only in individuals with recurrent depression. Antidepressants were not superior to PCT while tapering antidepressants (PCT/-AD). To inform decision-makers on treatment allocation, we present the corresponding cost-effectiveness, cost-utility and budget impact.Data were analysed (n = 289) using a societal perspective with 24-months of follow-up, with depression-free days and quality-adjusted life years (QALYs) as health outcomes. Incremental cost-effectiveness ratios were calculated and cost (...) Cost-effectiveness, cost-utility and the budget impact of antidepressants versus preventive cognitive therapy with or without tapering of antidepressants. As depression has a recurrent course, relapse and recurrence prevention is essential.AimsIn our randomised controlled trial (registered with the Nederlands trial register, identifier: NTR1907), we found that adding preventive cognitive therapy (PCT) to maintenance antidepressants (PCT+AD) yielded substantial protective effects versus

2019 BJPsych open Controlled trial quality: uncertain

20. Bariatric surgery: an HTA report on the efficacy, safety and cost-effectiveness

Bariatric surgery: an HTA report on the efficacy, safety and cost-effectiveness 2019 www.kce.fgov.be KCE REPORT 316 BARIATRIC SURGERY: AN HTA REPORT ON THE EFFICACY, SAFETY AND COST-EFFECTIVENESS 2019 www.kce.fgov.be KCE REPORT 316 HEALTH TECHNOLOGY ASSESSMENT BARIATRIC SURGERY: AN HTA REPORT ON THE EFFICACY, SAFETY AND COST-EFFECTIVENESS PETER LOUWAGIE, MATTIAS NEYT, DORIEN DOSSCHE, CÉCILE CAMBERLIN, BELINDA TEN GEUZENDAM, KOEN VAN DEN HEEDE, HANS VAN BRABANDT COLOPHON Title: Bariatric surgery (...) : an HTA report on the efficacy, safety and cost-effectiveness Authors: Peter Louwagie (KCE), Mattias Neyt (KCE), Dorien Dossche (KCE), Cécile Camberlin (KCE), Belinda ten Geuzendam (IMA – AIM), Koen Van den Heede (KCE), Hans Van Brabandt (KCE) Information retrieval support Patrice Chalon (KCE) Senior supervisor: Mattias Neyt (KCE) Reviewers: Jolyce Bourgeois (KCE), Irina Cleemput (KCE) External experts: Filip Ameye (RIZIV – INAMI - Rijksinstituut voor ziekte- en invaliditeitsverzekering – Institut

2019 Belgian Health Care Knowledge Centre

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>